List of Marijuana/Cannabinoid-Derived Drugs Companies in Pennsylvania - 3

Kannalife Sciences, Inc. ("Kannalife"), is a pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. Kannalife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "‘507 Patent"). Further, Kannalife has developed its own patented molecules lead by KLS-13019 called by TIME Magazine/SI as a "super-CBD" and was recently awarded U.S. Patent #9611213, "Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy et al.". Kannalife is currently conducting research and development at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, to treat Hepatic Encephalopathy ("HE"), Chronic Traumatic Encephalopathy ("CTE") and Chemotherapy Induced Peripheral Neuropathy ("CIPN"​). <​iframe width="560"​ height="315"​ src​="https://www.youtube.com/embed/LWLbe9m4JWo"​ frameborder="0"​ allow="autoplay; encrypted-media"​ allowfullscreen><​/iframe>

Kannalife Sciences, Inc. (a subsidiary of Neuropathix, Inc.) is a biopharmaceutical company focused on the research and development of a pipeline of next-generation pharmaceutical and phyto-medical products. The company is based in Doylestown, Pennsylvania and is known for its globally patented anti-inflammatory technology. Kannalife Sciences, Inc. is dedicated to the development of breakthrough therapeutics targeted for the treatment of inflammation and neurodegenerative diseases.

At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to transform the quality of lives of patients and their families as they battle these conditions. Our goal is to advance the science of therapeutic cannabinoids, and to improve the lives of patients battling severe neuropsychiatric conditions including Fragile X syndrome (FXS), Autism Spectrum Disorder (ASD), 22q, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE). Our approach is to utilize our pharmaceutically-manufactured, penetration-enhanced transdermal cannabinoid product candidate to modulate pathways in the central nervous system that, when disrupted, cause certain neurological diseases. By doing so, we hope to provide new treatment options for patients battling certain rare neuropsychiatric diseases. Acquired by Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) on Oct. 11, 2023.